

## PATENT ASSIGNMENT

Electronic Version v1.1  
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
The Institute for Pharmaceutical Discovery, LLC	05/15/2008
RECEIVING PARTY DATA	
Name:	Alinea Pharmaceuticals, Inc.
Street Address:	One Memorial Drive, Suite 1225
City:	Cambridge
State/Country:	MASSACHUSETTS
Postal Code:	02142
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	12701967
CORRESPONDENCE DATA	
Fax Number:	(312)913-0002
Phone:	312 913 0001
Email:	allen@mbhb.com
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>	
Correspondent Name:	McDonnell Boehnen Hulbert & Berghoff LLP
Address Line 1:	300 South Wacker Drive, Suite 3100
Address Line 4:	Chicago, ILLINOIS 60606
ATTORNEY DOCKET NUMBER:	99-046-QQ-CODIV
NAME OF SUBMITTER:	Steven J. Sarussi
Total Attachments: 9 source=Assignment_IPD_Alinea#page1.tif source=Assignment_IPD_Alinea#page2.tif source=Assignment_IPD_Alinea#page3.tif source=Assignment_IPD_Alinea#page4.tif	

CH \$40.00 12701967

source=Assignment\_IPD\_Alinea#page5.tif  
source=Assignment\_IPD\_Alinea#page6.tif  
source=Assignment\_IPD\_Alinea#page7.tif  
source=Assignment\_IPD\_Alinea#page8.tif  
source=Assignment\_IPD\_Alinea#page9.tif

## Appendix 1

### PATENT ASSIGNMENT

THIS PATENT ASSIGNMENT (this "Assignment") is made and delivered as of May 14, 2008 (the "Effective Date") by Institute for Diabetes Discovery, L.L.C., a Delaware limited liability company having an address of 23 Business Park Drive, Branford, CT 06405 ("IDD"), The Institutes for Pharmaceutical Discovery, L.L.C., a Delaware limited liability company and the parent company of IDD, having an address of 23 Business Park Drive, Branford, CT 06405 ("IPD"; IDD and IPD, together with their Affiliates, being sometimes collectively referred to herein as the "Assignor") for the benefit of Alinea Pharmaceuticals, Inc., a Delaware corporation having an address of One Memorial Drive, Suite 1225, Cambridge, MA 02142 ("Assignee"). Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Termination Agreement (as defined below).

### RECITALS

WHEREAS, Assignor and Assignee have entered into that certain Termination and Assignment Agreement (the "Termination Agreement"), dated as of May 14, 2008, pursuant to which, among other things, Assignor has agreed to sell, convey, transfer, assign and deliver to Assignee all of its right, title and interest in and to certain ARI Patent Rights, including the patents, patent applications and other patent filings set forth on Exhibit A, together with any and all international applications, divisionals, continuations, continuations-in-part, requests for continued examination, patents of addition, re-examinations, reissues, extensions, supplementary protection certifications, whether granted or not, substitutions, confirmations, registrations, revalidations, revisions, additions and the like, in each case of or to said patents, patent applications and other patent filings, and all inventions claimed therein and rights with respect thereto, and all causes of action, rights and remedies arising under any and all of such patents, patent applications and other patent filings (the "Patents").

NOW, THEREFORE, in consideration of the agreements and covenants contained in the Termination Agreement, and for other good and valuable consideration, the receipt, adequacy and sufficiency of which are hereby acknowledged, and subject to the terms and conditions of the Termination Agreement:

1. Assignment. Assignor hereby sells, assigns, transfers and conveys unto Assignee, and Assignee hereby purchases, accepts and assumes, all of Assignor's right, title and interest together with the benefits and privileges in and to said Patents; including all causes of action, rights and remedies arising under any and all of such Patents and the right to sue and recover for all past, present and future infringements thereof; together with the right to file (a) patents, patent applications and other patent filings claiming priority rights derived from the Patents under the patent laws of the United States, the International Convention for the Protection of Industrial Property, or any other international agreement or the domestic laws of the country in which any such patents, patent applications and other patent filings is filed, as may be applicable; and (b) all forms of industrial property protection, including, without limitation, patents, utility models, inventors' certificates, supplemental protection certificates and designs which may be granted for the inventions claimed in the Patents in any country or countries and all extensions, renewals and

IN WITNESS WHEREOF, Assignor has executed and delivered this Patent Assignment to Assignee.

ASSIGNOR:

Institute for Diabetes Discovery, L.L.C.

By: 

Name: James M. Nolan

Title: President + CEO

Date: May 15, 2008

The Institutes for Pharmaceutical Discovery, L.L.C.

By: 

Name: James M. Nolan

Title: President + CEO


Date: May 15, 2008

State of Connecticut

County of New Haven

On May 15, 2008 before me, Debra Zimmerman, Notary Public, personally appeared James Nolan and \_\_\_\_\_, personally known to me (or proved to me on the basis of satisfactory evidence) to be the persons whose names are subscribed to the within instrument and each acknowledged to me that he/she executed the same in his/her authorized capacity(ies), and that by his/her signature on the instrument the person, or the entity upon behalf of which the person acted, executed the instrument.

Witness my hand and official seal.

  
Notary Public

DEBRA S. ZIMMERMAN  
NOTARY PUBLIC  
MY COMMISSION EXPIRES JAN. 31, 2012

## EXHIBIT A

### List of Patents, Patent Applications and Other Patent Filings

<u>Patent No./Application No., Filing Date</u>	<u>Title</u>
6,214,991(US), 3/31/99	Substituted Indoleacetic Acids for Treatment of Diabetic complications (lidorestat)
AP2000011929 (AP), 9/30/00	Substituted Indoleacetic Acids for Treatment of Diabetic complications (lidorestat)
269861 (AT), 3/31/99	Substituted Indoleacetic Acids for Treatment of Diabetic complications (lidorestat)
34595/99 (AU), 3/31/99	Substituted Indoleacetic Acids for Treatment of Diabetic complications (lidorestat)
104819 (BG), 3/31/99	Substituted Indoleacetic Acids for Treatment of Diabetic complications (lidorestat)
P199093588 (BR), 3/31/99	Substituted Indoleacetic Acids for Treatment of Diabetic complications (lidorestat)
2383983 (CA), 3/31/99	Substituted Indolealkanoic Acids for Treatment of Diabetic complications (lidorestat)
99916239.9 (CH), 3/31/99	Substituted Indoleacetic Acids for Treatment of Diabetic complications (lidorestat)
99804773.2 (CN), 3/31/99	Substituted Indoleacetic Acids for Treatment of Diabetic complications (lidorestat)
PV2000/3607 (CZ), 3/31/99	Substituted Indoleacetic Acids for Treatment of Diabetic complications (lidorestat)
69918278.6 (DE), 3/31/99	Substituted Indoleacetic Acids for Treatment of Diabetic complications (lidorestat)
2764 (DZ), 4/10/99	Substituted Indoleacetic Acids for Treatment of Diabetic complications (lidorestat)
200000573 (EE), 3/31/99	Substituted Indoleacetic Acids for Treatment of Diabetic complications (lidorestat)
99916239.9 (EP), 3/31/99	Substituted Indoleacetic Acids for Treatment of Diabetic complications (lidorestat)
2224632 (ES), 3/31/99	Substituted Indoleacetic Acids for Treatment of Diabetic complications (lidorestat)
99916239.9 (FR), 3/31/99	Substituted Indoleacetic Acids for Treatment of Diabetic complications (lidorestat)
99916239.9 (GB), 3/31/99	Substituted Indoleacetic Acids for Treatment of Diabetic complications (lidorestat)
01104718.2 (HK), 7/9/01	Substituted Indoleacetic Acids for Treatment of Diabetic complications (lidorestat)
P0101672 (HU), 3/31/99	Substituted Indoleacetic Acids for Treatment of Diabetic complications (lidorestat)
20002212 (ID), 3/31/99	Substituted Indoleacetic Acids for Treatment of Diabetic complications (lidorestat)
99916239.9 (IE), 3/31/99	Substituted Indoleacetic Acids for Treatment of Diabetic complications (lidorestat)
138711 (IL), 3/31/99	Substituted Indoleacetic Acids for Treatment of Diabetic complications (lidorestat)
00/00457 (IN), 3/31/99	Substituted Indoleacetic Acids for Treatment of Diabetic complications (lidorestat)
71591/BE/2004 (IT), 3/31/99	Substituted Indoleacetic Acids for Treatment of Diabetic complications (lidorestat)

2000-541171 (JP), 3/31/99	Substituted Indoleacetic Acids for Treatment of Diabetic complications (lidorestat)
2002-290240 (JP), 11/2/02	Substituted Indoleacetic Acids for Treatment of Diabetic complications (lidorestat)
2000-7010884 (KR), 3/31/99	Substituted Indoleacetic Acids for Treatment of Diabetic complications (lidorestat)
99916239.9 (LT), 3/31/99	Substituted Indoleacetic Acids for Treatment of Diabetic complications (lidorestat)
99916239.9 (LU), 3/31/99	Substituted Indoleacetic Acids for Treatment of Diabetic complications (lidorestat)
99916239.9 (MC), 3/31/99	Substituted Indoleacetic Acids for Treatment of Diabetic complications (lidorestat)
2003122 (MX), 3/31/99	Substituted Indoleacetic Acids for Treatment of Diabetic complications (lidorestat)
P19901343 (MY), 4/7/99	Substituted Indoleacetic Acids for Treatment of Diabetic complications (lidorestat)
86/99 (NG), 4/14/99	Substituted Indoleacetic Acids for Treatment of Diabetic complications (lidorestat)
99916239.9 (NL), 3/31/99	Substituted Indoleacetic Acids for Treatment of Diabetic complications (lidorestat)
507172 (NZ), 3/31/99	Substituted Indoleacetic Acids for Treatment of Diabetic complications (lidorestat)
200004900 (NO), 3/31/99	Substituted Indoleacetic Acids for Treatment of Diabetic complications (lidorestat)
11622 (OA), 3/31/99	Substituted Indoleacetic Acids for Treatment of Diabetic complications (lidorestat)
1-1999-00767 (PH), 4/7/99	Substituted Indoleacetic Acids for Treatment of Diabetic complications (lidorestat)
P-348244 (PL), 3/31/99	Substituted Indoleacetic Acids for Treatment of Diabetic complications (lidorestat)
99916239.9 (PT), 3/31/99	Substituted Indoleacetic Acids for Treatment of Diabetic complications (lidorestat)
2000 05390-0 (SG), 3/31/99	Substituted Indoleacetic Acids for Treatment of Diabetic complications (lidorestat)
PV0752-2001S (SK), 3/31/99	Substituted Indoleacetic Acids for Treatment of Diabetic complications (lidorestat)
053021 (TH), 9/28/99	Substituted Indoleacetic Acids for Treatment of Diabetic complications (lidorestat)
2000/2869 (TR), 3/31/99	Substituted Indoleacetic Acids for Treatment of Diabetic complications (lidorestat)
088109147 (TW), 6/2/99	Substituted Indoleacetic Acids for Treatment of Diabetic complications (lidorestat)
2000/5577 (ZA), 3/31/99	Substituted Indoleacetic Acids for Treatment of Diabetic complications (lidorestat)
6,555,568(US), 12/1/99	Substituted Indoleacetic Acids for Treatment of Diabetic Complications and Elevated Triglyceride Levels, Glucose Lowering, Wound Healing
2006/0074114 (US), 4/6/06	Methods of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis using substituted indolealkanoic acids
2001/02146 (AP), 12/1/99	Methods of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis using substituted indolealkanoic acids
265210 (AT), 12/1/99	Methods of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis using substituted indolealkanoic acids



2161600 (AU), 12/1/99	Methods of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis using substituted indolealkanoic acids
105531 (BG), 12/1/99	Methods of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis using substituted indolealkanoic acids
9915882 (BR), 12/1/99	Methods of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis using substituted indolealkanoic acids
2385845 (CA), 12/1/99	Methods of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis using substituted indolealkanoic acids
136883 (CN), 12/1/99	Methods of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis using substituted indolealkanoic acids
PV2001-1864 (CZ), 12/1/99	Compounds of substituted indole alkanolic acids and their use for increasing serum concentrations of triglycerides
69916881.3 (DE), 12/1/99	Methods of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis using substituted indolealkanoic acids
2953 (DZ), 12/1/99	Methods of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis using substituted indolealkanoic acids
200100296 (EE), 12/1/99	Methods of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis using substituted indolealkanoic acids
99965955.0 (EP), 12/1/99	Antihypertriglyceridemic, Antihypertensive, Antiangiogenic and Wound Healing Substituted indolealkanoic acids
99965955.0 (FR), 12/1/99	Antihypertriglyceridemic, Antihypertensive, Antiangiogenic and Wound Healing Substituted indolealkanoic acids
99965955.0 (GB), 12/1/99	Antihypertriglyceridemic, Antihypertensive, Antiangiogenic and Wound Healing Substituted indolealkanoic acids
02107989.6 (HK), 11/2/02	Methods of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis using substituted indolealkanoic acids
0104953 (HU), 12/1/99	Methods of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis using substituted indolealkanoic acids
W-200101404 (ID), 12/1/99	Methods of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis using substituted indolealkanoic acids
143247 (IL), 12/1/99	Methods of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis using substituted indolealkanoic acids

99965955.0 (IT), 12/1/99	Substituted Indoleacetic Acids for Treatment of Diabetic Complications and Elevated Triglyceride Levels, Glucose Lowering, Wound Healing
200531398 (JP), 12/1/99	Methods of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis using substituted indolealkanoic acids
20031118 (MX), 12/1/99	Methods of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis using substituted indolealkanoic acids
390'99 (NG), 12/1/99	Methods of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis using substituted indolealkanoic acids
20012690 (NO), 12/1/99	Methods of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis using substituted indolealkanoic acids
12035 (OA), 12/1/99	Methods of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis using substituted indolealkanoic acids
P-349016 (PL), 12/1/99	Methods of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis using substituted indolealkanoic acids
PV0735-2001S (SK), 12/1/99	Methods of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis using substituted indolealkanoic acids
200101539 (TR), 12/1/99	Methods of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis using substituted indolealkanoic acids
584560 (TW), 2/1/00	Pharmaceutical composition of substituted indolealkanoic acids for reducing serum glucose and triglyceride levels and inhibiting angiogenesis
1-2001-00613 (VN), 12/1/99	Substituted Indoleacetic Acids for Treatment of Diabetic Complications and Elevated Triglyceride Levels, Glucose Lowering, Wound Healing
200104126 (ZA), 5/21/01	Methods of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis using substituted indolealkanoic acids
6,521,659 (US), 2/28/01	Substituted Indolealkanoic Acid Compositions and an ACE Inhibitor
6,730,794 (US), 6/28/02	Substituted Indolealkanoic Acids - Continuation
7,105,514 (US), 9/12/06	Substituted Indolealkanoic Acids - Continuation
7,304,079 (US), 12/4/07	Substituted Indolealkanoic Acids - Continuation
11/999,524 (US), 12/4/07	Substituted Indolealkanoic Acids - Continuation
10/522642 (US), 7/28/03	Substituted Indolealkanoic Acid Derivatives...For Use in Treatment of Diabetic Complications
2003256926 (AU), 7/28/03	Substituted Indolealkanoic Acid Derivatives...For Use in Treatment of Diabetic Complications
PI0312972-1 (BR), 7/28/03	Substituted Indolealkanoic Acid Derivatives...For Use in Treatment of Diabetic Complications



2395871 (CA), 7/26/02	Substituted Indolealkanoic Acid Derivatives...For Use in Treatment of Diabetic Complications
2493755 (CA), 7/28/03	Substituted Indolealkanoic Acid Derivatives...For Use in Treatment of Diabetic Complications
03822906.4 (CN), 7/28/03	Substituted Indolealkanoic Acid Derivatives...For Use in Treatment of Diabetic Complications
03771964.8 (EP), 7/28/03	Substituted Indolealkanoic Acid Derivatives...For Use in Treatment of Diabetic Complications
2004524941 (JP), 7/28/03	Substituted Indolealkanoic Acid Derivatives...For Use in Treatment of Diabetic Complications
20057001435 (KR), 7/28/03	Substituted Indolealkanoic Acid Derivatives...For Use in Treatment of Diabetic Complications
2005001011 (MX), 7/28/03	Substituted Indolealkanoic Acid Derivatives...For Use in Treatment of Diabetic Complications
6,964,980 (US), 03-26-03	Substituted indoleacetic acids/ Wound healing - Continuation
6,426,344 (US), 3/27/01	Aryl and Heteroaryl Substituted Indolealkanoic Acids
10/832,724 (US), 4/27/04	Substituted Indoleacetic Acids

*Other ARI Cases*

6,420,426 (US), 6/23/00	Substituted Phenoxyacetic Acids
7,189,749 (US), 9/12/03	Substituted Phenoxyacetic Acids
200102377 (AP), 6/30/00	Substituted Phenoxyacetic Acids
5886900 (AU), 6/30/00	Substituted Phenoxyacetic Acids
106351 (BG), 6/23/00	Substituted Phenoxyacetic Acids
0011928 (BR), 6/30/00	Substituted Phenoxyacetic Acids
2385798 (CA), 6/30/00	Substituted Phenoxyacetic Acids
00809446.2 (CN), 6/23/00	Substituted Phenoxyacetic Acids
20014637 (CZ), 6/30/00	Substituted Phenoxyacetic Acids
200100708 (FE), 6/30/00	Substituted Phenoxyacetic Acids
1198451 (EP), 6/30/00	Substituted Phenoxyacetic Acids
0202384 (HU), 6/30/00	Substituted Phenoxyacetic Acids
147197 (IL), 6/23/00	Substituted Phenoxyacetic Acids

2001-506979 (JP), 6/23/00

Substituted Phenoxyacetic Acids

**PATENT**

**REEL: 027792 FRAME: 0322**

PA02003123 (MX), 6/30/00	Substituted Phenoxyacetic Acids
222/2000 (NG), 6/30/00	Substituted Phenoxyacetic Acids
20016272 (NO), 12/20/01	Substituted Phenoxyacetic Acids
516290 (NZ), 6/23/00	Substituted Phenoxyacetic Acids
11972 (OA), 6/23/00	Substituted Phenoxyacetic Acids
P355857 (PL), 6/23/00	Substituted Phenoxyacetic Acids
19152001 (SK), 6/23/00	Substituted Phenoxyacetic Acids
058545 (TH), 6/26/00	Substituted Phenoxyacetic Acids
200200619 (TR), 6/23/00	Substituted Phenoxyacetic Acids
089112529 (TW), 7/11/00	Substituted Phenoxyacetic Acids
1-2002-00092 (VN), 6/23/00	Substituted Phenoxyacetic Acids
10,295,414(US), 11/14/02	Substituted Heteroarylcanoic Acid Derivatives
P020104506 (AR), 11/22/02	Substituted Heteroarylcanoic Acid Derivatives
2002350191 (AU), 11/15/02	Substituted Heteroarylcanoic Acid Derivatives
2466925 (CA), 11/15/02	Substituted Heteroarylcanoic Acid Derivatives
02786720.9 (EP), 11/15/02	Substituted Heteroarylcanoic Acid Derivatives
2003545652 (JP), 11/15/02	Substituted Heteroarylcanoic Acid Derivatives
PAa2004004548 (MX), 11/15/02	Substituted Heteroarylcanoic Acid Derivatives